4.5 Review

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Journal

CLINICAL AND MOLECULAR HEPATOLOGY
Volume 29, Issue -, Pages S207-S219

Publisher

KOREAN ASSOC STUDY LIVER
DOI: 10.3350/cmh.2022.0247

Keywords

Liver neoplasm; Non-alcoholic fatty liver disease; Early detection of cancer; Population surveillance; Hepatocellular carcinoma

Ask authors/readers for more resources

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of hepatocellular carcinoma (HCC), and HCC surveillance is recommended for patients with cirrhosis from any cause and may be beneficial for high-risk subgroups with non-cirrhotic NAFLD. NAFLD-related HCC patients are more likely to have advanced stage cancer and poor outcomes due to suboptimal effectiveness of surveillance programs. This review summarizes current HCC surveillance guidelines, discusses challenges specific to NAFLD, and examines the effectiveness of current surveillance tools while suggesting future approaches to improve adherence.
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non- cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available